Measures against illegal fresh-cell therapy offers and unauthorized fresh-cell preparations
regulatory notice · 2015
LINK
SUMMARY
Joint official assessment by the Swiss Federal Office of Public Health and Swissmedic. It defines Paul Niehans's original fresh-cell therapy as the transfer to humans of live animal cells, usually from fetal sheep organs or placenta, for claimed revitalization. The authorities report no scientifically demonstrated efficacy and substantial risks, including hypersensitivity, injection-site abscess and sepsis, zoonotic infection, autoimmune disease, and reported deaths. They state that live animal-cell use is xenotransplantation requiring federal authorization and that neither agency had granted a relevant Swiss marketing, manufacturing, or use authorization. The article also records that Germany's attempted federal ban of fresh-cell production was voided on formal constitutional grounds in 2000; it does not support a blanket-ban claim.
NOTES
This joint Swiss regulatory assessment directly addresses the Niehans procedure, its claimed anti-aging and organ-revitalizing uses, the absence of demonstrated efficacy, and its documented risk profile. It distinguishes live animal-cell xenotransplantation from nonliving cell extracts and explains the authorization regime applicable to each. The article is the archive’s primary evidence for the treatment’s modern Swiss regulatory status; it replaces the unsupported conventional 1985 ban date previously used in the corpus.